Nisa Investment Advisors LLC Decreases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Nisa Investment Advisors LLC lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,232 shares of the biopharmaceutical company’s stock after selling 190 shares during the period. Nisa Investment Advisors LLC’s holdings in Intra-Cellular Therapies were worth $303,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ITCI. Vanguard Group Inc. raised its holdings in Intra-Cellular Therapies by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company’s stock valued at $444,834,000 after buying an additional 43,689 shares during the last quarter. BlackRock Inc. raised its stake in shares of Intra-Cellular Therapies by 13.1% during the first quarter. BlackRock Inc. now owns 6,470,417 shares of the biopharmaceutical company’s stock valued at $395,924,000 after acquiring an additional 748,651 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Intra-Cellular Therapies during the first quarter worth about $248,502,000. State Street Corp grew its stake in shares of Intra-Cellular Therapies by 3.9% in the second quarter. State Street Corp now owns 2,105,705 shares of the biopharmaceutical company’s stock worth $133,333,000 after purchasing an additional 79,477 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Intra-Cellular Therapies by 4.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after purchasing an additional 86,388 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $72.00 on Friday. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89. The firm has a 50-day moving average of $69.31 and a 200 day moving average of $63.82. The stock has a market cap of $6.97 billion, a P/E ratio of -50.38 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business had revenue of $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The business’s revenue for the quarter was up 50.3% on a year-over-year basis. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the transaction, the executive vice president now owns 16,170 shares in the company, valued at $1,076,275.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Michael Halstead sold 7,345 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.97, for a total transaction of $484,549.65. Following the sale, the executive vice president now directly owns 19,803 shares of the company’s stock, valued at $1,306,403.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the sale, the executive vice president now directly owns 16,170 shares in the company, valued at approximately $1,076,275.20. The disclosure for this sale can be found here. Insiders have sold 168,487 shares of company stock worth $11,364,950 in the last 90 days. Insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

ITCI has been the subject of several research analyst reports. Canaccord Genuity Group dropped their price objective on Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating for the company in a report on Friday, February 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $101.00 price objective on shares of Intra-Cellular Therapies in a research report on Friday, February 23rd. Mizuho raised their target price on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Finally, The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.17.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.